TCT-14 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) After PCI in Brazil and Japan: SYNERGY Stent With Prasugrel Monotherapy (10 mg or 3.75 mg)

Yoshinobu Onuma; Takashi Muramatsu; Ken Kozuma; Yuki Ishibashi; Kuniaki Takahashi; Kengo Tanabe; Norihiro Kogame; Masato Nakamura; Taku Asano; Yosuke Miyazaki; Shimpei Nakatani; Yuki Katagiri; Yoshihiro Morino; Shinichiro Masuda; Kai Ninomiya; Shigetaka Kageyama; Nozomi Kotoku; Patrick W. Serruys

doi:10.1016/j.jacc.2022.08.023

Article2023

A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without Aspirin

Yoshinobu Onuma, Shinichiro Masuda, Takashi Muramatsu, Yuki Ishibashi, Ken Kozuma, Hideyuki Kawashima, Gaku Nakazawa, Kuniaki Takahashi, Kengo Tanabe, Norihiro Kogame, Masato Nakamura, Taku Asano, Takayuki Okamura, Yosuke Miyazaki, Hiroki Tateishi, Yukio Ozaki, Shimpei Nakatani, Yuki Katagiri, Yoshihiro Morino, Kai Ninomiya, Shigetaka Kageyama, Nozomi Kotoku, Patrícia O. Guimarães, Pedro A. Lemos, Patrick W. Serruys

Cardiovascular revascularization medicine

Article2023

CRT-100.33 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without Aspirin

Yoshinobu Onuma, Shinichiro Masuda, Takashi Muramatsu, Yuki Ishibashi, Ken Kozuma, Hideyuki Kawashima, Gaku Nakazawa, Kuniaki Takahashi, Kengo Tanabe, Norihiro Kogame, Masato Nakamura, Taku Asano, Takayuki Okamura, Yosuke Miyazaki, Hiroki Tateishi, Yukio Ozaki, Shimpei Nakatani, Yuki Katagiri, Yoshihiro Morino, Kai Ninomiya, Shigetaka Kageyama, Nozomi Kotoku, ,

Article2023

TCTAP A-046 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) In Brazil and Japan: Synergy Stent With Prasugrel Monotherapy Without Aspirin

Yuki Ishibashi, Shinichiro Masuda, Takashi Muramatsu, Ken Kozuma, Hideyuki Kawashima, Gaku Nakazawa, Kuniaki Takahashi, Kengo Tanabe, Norihiro Kogame, Masato Nakamura, Taku Asano, Takayuki Okamura, Yosuke Miyazaki, Hiroki Tateishi, Yukio Ozaki, Shimpei Nakatani, Yuki Katagiri, Yoshihiro Morino, Kai Ninomiya, Shigetaka Kageyama, Nozomi Kotoku, Patrícia O. Guimarães, ,

Article2024

TCT-231 Safety of Aspirin-Free Prasugrel Monotherapy After PCI: Pooled Analysis of Three Months Outcomes in 508 Patients From ASET-I and ASET-Japan Trials

Kotaro Miyashita, Takashi Muramatsu, Gaku Nakazawa, Yuki Ishibashi, Yoshinobu Onuma, Pedro A. Lemos, Patrick W. Serruys

Journal of the American College of Cardiology

Article2022

TCT-304 Non-Invasive Assessment of Microvascular Dysfunction After Optimal Coronary Artery Stent Deployment; Insight From Acetyl Salicylic Elimination Trial (ASET) Japan

Shinichiro Masuda, Jinying Zhou, Shigetaka Kageyama, Kai Ninomiya, Nozomi Kotoku, Pruthvi Chenniganahosahalli Revaiah, Yoshinobu Onuma, Patrick W. Serruys

Journal of the American College of Cardiology

TCT-14 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) After PCI in Brazil and Japan: SYNERGY Stent With Prasugrel Monotherapy (10 mg or 3.75 mg)

Abstract

Discussion(0)

Related publications

A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without Aspirin

CRT-100.33 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) in Brazil and Japan: Synergy Stent with Prasugrel Monotherapy Without Aspirin

TCTAP A-046 A 30-Day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) In Brazil and Japan: Synergy Stent With Prasugrel Monotherapy Without Aspirin

TCT-231 Safety of Aspirin-Free Prasugrel Monotherapy After PCI: Pooled Analysis of Three Months Outcomes in 508 Patients From ASET-I and ASET-Japan Trials

TCT-304 Non-Invasive Assessment of Microvascular Dysfunction After Optimal Coronary Artery Stent Deployment; Insight From Acetyl Salicylic Elimination Trial (ASET) Japan